Overall, the novelty of our study is based on the application of an immunohistochemical panel made up of five antibodies (HBME-1, Gal-3, Ki-67, BRAF V600E, and p53) to detect malignant TA-treated thyroid nodules. Here, BRAF is linked to thyroid nodule.